Don't Buy argenx SE Before Checking Its Fundamentals!

By Naomi Wentworth • Thursday, July 31 15:19 • Permanent Link

Shares of Biotechnology company argenx SE jumped 11.6% today. With many investors piling into ARGX without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

argenx SE has moved 16.0% over the last year, and the S&P 500 logged a change of 16.8%
ARGX has an average analyst rating of buy and is -9.89% away from its mean target price of $741.58 per share
Its trailing earnings per share (EPS) is $16.41
argenx SE has a trailing 12 month Price to Earnings (P/E) ratio of 40.7 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $9.69 and its forward P/E ratio is 69.0
The company has a Price to Book (P/B) ratio of 7.38 in contrast to the S&P 500's average ratio of 4.74
argenx SE is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.